Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

N-acetylcysteine attenuates iodine contrast agent-induced nephropathy in 5/6-nephrectomized rats

Jan Šochman, Jan H. Peregrin, Marcela Bürgelová, Libor Kopkan, Herbert J. Kramer, Luděk Červenka

. 2010 ; 33 (2) : 149-156. [pub] 20100526

Language English Country Switzerland

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc12025686

Grant support
NS10499 MZ0 CEP Register

AIMS: In the present study we tested the efficacy of N-acetylcysteine (NAC) to minimize nephrotoxic effects of iodine contrast agents in intact rats as well as in 5/6-nephrectomized (5/6-Nx) rats. METHODS: Rats were allocated to a group of intact rats (n = 42) and a group of 5/6-Nx rats (n = 42). After 1 month of recovery from surgery, 5/6-Nx rats and intact (sham-operated) animals received either 6 ml/kg body weight (b.w.) meglumine ioxithalamate (Telebrix 350) or 6 ml/kg b.w. iohexol (Omnipaque 350) intravenously with or without pretreatment with 100 mg/kg b.w. NAC. Plasma and urinary concentrations of creatinine, sodium and protein in 24-hour urine collections were determined prior to and on days 1, 3 and 7 after drug administration. RESULTS: In intact animals, contrast agents caused no significant changes in kidney function throughout the duration of the experiment. In contrast, significant increases in plasma creatinine levels and decreases in creatinine clearance were induced by both contrast agents in 5/6-Nx rats. These changes were significantly attenuated by NAC pretreatment. CONCLUSION: The results of the present study demonstrate that iodine contrast agent-induced nephropathy in 5/6-Nx rats is significantly attenuated by intravenous pretreatment with NAC.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12025686
003      
CZ-PrNML
005      
20170411100119.0
007      
ta
008      
120817s2010 sz f 000 0#eng||
009      
AR
024    7_
$a 10.1159/000315435 $2 doi
035    __
$a (PubMed)20502036
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Šochman, Jan $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
245    10
$a N-acetylcysteine attenuates iodine contrast agent-induced nephropathy in 5/6-nephrectomized rats / $c Jan Šochman, Jan H. Peregrin, Marcela Bürgelová, Libor Kopkan, Herbert J. Kramer, Luděk Červenka
520    9_
$a AIMS: In the present study we tested the efficacy of N-acetylcysteine (NAC) to minimize nephrotoxic effects of iodine contrast agents in intact rats as well as in 5/6-nephrectomized (5/6-Nx) rats. METHODS: Rats were allocated to a group of intact rats (n = 42) and a group of 5/6-Nx rats (n = 42). After 1 month of recovery from surgery, 5/6-Nx rats and intact (sham-operated) animals received either 6 ml/kg body weight (b.w.) meglumine ioxithalamate (Telebrix 350) or 6 ml/kg b.w. iohexol (Omnipaque 350) intravenously with or without pretreatment with 100 mg/kg b.w. NAC. Plasma and urinary concentrations of creatinine, sodium and protein in 24-hour urine collections were determined prior to and on days 1, 3 and 7 after drug administration. RESULTS: In intact animals, contrast agents caused no significant changes in kidney function throughout the duration of the experiment. In contrast, significant increases in plasma creatinine levels and decreases in creatinine clearance were induced by both contrast agents in 5/6-Nx rats. These changes were significantly attenuated by NAC pretreatment. CONCLUSION: The results of the present study demonstrate that iodine contrast agent-induced nephropathy in 5/6-Nx rats is significantly attenuated by intravenous pretreatment with NAC.
650    _2
$a acetylcystein $x aplikace a dávkování $x farmakologie $7 D000111
650    _2
$a zvířata $7 D000818
650    _2
$a kontrastní látky $x škodlivé účinky $7 D003287
650    _2
$a jod $x škodlivé účinky $7 D007455
650    _2
$a johexol $x škodlivé účinky $7 D007472
650    _2
$a meglumin-jothalamát $x škodlivé účinky $7 D007482
650    _2
$a nemoci ledvin $x chemicky indukované $x prevence a kontrola $7 D007674
650    _2
$a nefrektomie $7 D009392
650    _2
$a premedikace $x metody $7 D011292
650    _2
$a krysa rodu Rattus $7 D051381
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Peregrin, Jan H. $u Department of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Bürgelová, Marcela $u Nephrology and Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Kopkan, Libor $u Department of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center for Cardiovascular Research, Prague, Czech Republic
700    1_
$a Kramer, Herbert J. $u Section of Nephrology, Medical Policlinic, Department of Medicine, University of Bonn, Bonn, Germany
700    1_
$a Červenka, Luděk $u Department of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Physiology, 2nd Medical Faculty, Charles University, Prague, Czech Republic
773    0_
$w MED00003064 $t Kidney & blood pressure research $x 1423-0143 $g Roč. 33, č. 2 (2010), s. 149-156
856    41
$u https://pubmed.ncbi.nlm.nih.gov/20502036 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120817 $b ABA008
991    __
$a 20170411100418 $b ABA008
999    __
$a ok $b bmc $g 947728 $s 783032
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2010 $b 33 $c 2 $d 149-156 $e 20100526 $i 1423-0143 $m Kidney & blood pressure research $n Kidney Blood Press Res $x MED00003064
GRA    __
$a NS10499 $p MZ0
LZP    __
$a Pubmed-20120817/10/03

Find record

Citation metrics

Archiving options